Ono Pharmaceutical Co., Ltd.- Strategy and SWOT Report


February 22, 2012
36 Pages - SKU: MTLN3936987
License type:
Ono Pharmaceutical Co., Ltd. - Strategy and SWOT Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360° view of the company.

Features:
  • Detailed information on Ono Pharmaceutical Co., Ltd. required for business and competitor intelligence needs
  • A study of the major internal and external factors affecting Ono Pharmaceutical Co., Ltd. in the form of a SWOT analysis
  • An in-depth view of the business model of Ono Pharmaceutical Co., Ltd. including a breakdown and examination of key business segments
  • Intelligence on Ono Pharmaceutical Co., Ltd.’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
  • News about Ono Pharmaceutical Co., Ltd., such as business expansion, restructuring, and contract wins
  • Large number of easy-to-grasp charts and graphs that present important data and key trends
Highlights:

Ono Pharmaceutical (Ono) is engaged in the production, purchase and sale of pharmaceuticals and diagnostic reagents focusing primarily on prescription pharmaceuticals. It offers drugs for the treatment of bronchial asthma, diabetic peripheral neuropathy, intra-operative and postoperative tachyarrhythmia and overactive bladder. The company operates in Japan. It is headquartered in Osaka, Japan and employed 2,418 people as of March 2011. The company recorded revenues of JPY135,255 million (approximately $1,582.5 million) during the financial year ended March 2011 (FY2011), a decrease of 0.5% compared with FY2010. The operating profit of the company was JPY35,201 million (approximately $411.9 million) during FY2011, a decrease of 11.6% compared with FY2010. The net profit was JPY24,222 million (approximately $283.4 million) in FY2011, a decrease of 13.1% compared with FY2010.

Reasons to Purchase:
  • Gain understanding of Ono Pharmaceutical Co., Ltd. and the factors that influence its strategies
  • Track strategic initiatives of the company and latest corporate news and actions
  • Assess Ono Pharmaceutical Co., Ltd. as a prospective partner, vendor or supplier
  • Support sales activities by understanding your customers' businesses better
  • Stay up to date on Ono Pharmaceutical Co., Ltd.’s business structure, strategy and prospects



More Pharmaceuticals Company reports by MarketLine

Catalent Pharma Solutions, Inc. - Strategy and SWOT Report by MarketLine
Catalent Pharma Solutions, Inc. - Strategy and SWOT Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, ...
CSL Limited - SWOT, Strategy and Corporate Finance Report by MarketLine
CSL Limited - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, ...
Dainippon Sumitomo Pharma Co., Ltd. - SWOT, Strategy and Corporate Finance Report by MarketLine
Dainippon Sumitomo Pharma Co., Ltd. - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the ...
Pfizer Inc: Re-entry to the OTC healthcare market by MarketLine
Introduction Pfizer, Inc. was originally founded as fine chemicals business. Following a series of product developments and M&A deals the company is now present ...
See all reports like this >>

 
Research assistance
We can help you find what you need. Call us or write us:
US: 800.298.5699
Int'l: +1.240.747.3093
Need help in your search?
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!